Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Eukaryotic Gene Expression
Импакт фактор: 2.156 5-летний Импакт фактор: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN Печать: 1045-4403
ISSN Онлайн: 2162-6502

Том 30, 2020 Том 29, 2019 Том 28, 2018 Том 27, 2017 Том 26, 2016 Том 25, 2015 Том 24, 2014 Том 23, 2013 Том 22, 2012 Том 21, 2011 Том 20, 2010 Том 19, 2009 Том 18, 2008 Том 17, 2007 Том 16, 2006 Том 15, 2005 Том 14, 2004 Том 13, 2003 Том 12, 2002 Том 11, 2001 Том 10, 2000 Том 9, 1999 Том 8, 1998 Том 7, 1997 Том 6, 1996 Том 5, 1995 Том 4, 1994

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.2015015601
pages 363-369

Hypoxia Is the Driving Force Behind GBM and Could Be a New Tool in GBM Treatment

Rasime Kalkan
Near East University, Faculty of Medicine, Department of Medical Genetics, Cyprus

Краткое описание

Glioblastoma (GBM) can be divided into two distinct disease entities according to the genetic and the epigenetic background of the tumor. Tumor location is associated with high variability in its genetic abnormalities. The treatment procedures for these tumors are often unsuccessful because of the cellular heterogeneity and intrinsic ability of the tumor cells to invade healthy tissues. The fatal outcomes of these tumors have encouraged researchers to find new markers associated with prognosis and treatment planning. In the present communication, we discuss hypoxia as a new therapeutic target of glioblastoma multiforme and the molecular and phenotypic effects of hypoxia on cancer cells. We focus on the inhibition of the signaling pathways, which is associated with the hypoxia-mediated maintenance of glioblastoma stem cells and the knockdown of the hypoxia-inducible factor 1-alpha (HIFlα). This discussion may contribute to the development of new specifically targeted treatments. Furthermore, we highlight the idea that hypoxia-inducible factors (HIFs) could be attractive molecular targets for GBM therapeutics.

Ключевые слова: stem cell, glioblastoma stem cell, therapy, hypoxia, mutation

Articles with similar content:

Glioblastoma Multiforme: The Genetic Perspective of the Treatment Planning
Critical Reviews™ in Eukaryotic Gene Expression, Vol.25, 2015, issue 4
Rasime Kalkan
Resistance to Cell Death and Its Modulation in Cancer Stem Cells
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 3-4
Ahmad R. Safa
RKIP-Mediated Chemo-Immunosensitization of Resistant Cancer Cells via Disruption of the NF-κB/Snail/YY1/RKIP Resistance-Driver Loop
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 6
Benjamin Bonavida
Cancer Stem Cells: Root of the Evil
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 1
Didem Karakas, Merve Erkisa, Engin Ulukaya
Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 2
Abdul Kareem Khan, Mamoon Ur Rashid, Ishtiaq Hussain, Sarfraz Ahmad, Asad Ur Rahman, Sundas Jehanzeb, Akriti Gupta Jain, Deepika Sarvepalli, Neelam Khetpal, Waqas Ullah, Badar Hasan